Author Archives: Scalper1

Preparing For A Market Collapse, Part III

Summary U.S. equities are down but not cheap. They could fall further. It is time to prepare…. … In fact, it is always a good time to be prepared. This is the third in a series. You can read Part I and Part II for background. Since the series began, the S&P 500 (NYSEARCA: SPY ) is down over 10%; it could have much further to fall. What current shorts have the most asymmetric exposure? How can average investors see the need to short? Here are three specific short ideas followed by three ways for investors, including retail investors, to weigh when to short. China In terms of country exposure, China is among my favorite shorts. Artificial central bank stimulus drove the Chinese equity mania in early 2015. New equity buyers flooded into the market. These new investors purchased stocks using a record amount of margin debt. They had weak hands once the market direction turned around. The supply of new capital was finite. Eager new investors pushed up prices, but quickly pulled out of the market once prices declined. How do you short China? One way is to short Direxion Daily China Bull 3X Shares (NYSEARCA: YINN ). It is down over 70% since I first disclosed this idea, but it could drop much further over time. That being said, not all Chinese equities are expensive. While China is a big short idea overall, there are some small long ideas worth considering, such as Taomee (NYSE: TAOM ). Biotech Turning to sector exposure, biotech is another favorite short opportunity. This has been a hot sector, but one with market prices that are high, unstable, and precarious . It is down over 20% but remains overpriced. In the long term, it will probably decline substantially further. While biotech is a major short opportunity, one can find bargains in the wreckage. Depomed (NASDAQ: DEPO ) is one worth considering. Due to its drug prices, it is far less sensitive to political pressure than Horizon (NASDAQ: HZNP ) or Valeant (NYSE: VRX ). High Yield In the current credit environment, “high yield” is a bit of a misnomer. In fact, it borders on false advertising. This is one of my favorite types of securities to short because high yield is expensive enough that it does not cost too much if it maintains these rarified prices, and investors long this exposure will probably not hang in there if it begins to decline substantially. Retail investors (including not just a few on Seeking Alpha) who seek yield at any price have driven securities with the appearance of stable yield to zany prices. One security to consider is PIMCO High Income Fund (NYSE: PHK ). As of today, it trades at a 13% premium to its NAV. Down over 25%, it is still overpriced. Its price should continue to converge upon its value in the years ahead. If credit spreads widen from here, it could decline substantially. Should you own any broad-based bond exposure? At today’s prices, no. “HPHs [high priced helpers] frequently think of risk as a function of asset class along the lines of “cash is safe, stock is risky, and bonds are in the middle”. In reality, risk is never a function of asset class; it is a function of price. Thinking proxies such as asset class-based risk models are designed only to excuse HPHs from doing any fundamental analysis to determine value. They can’t make you safe because they can’t even define, let alone quantify, risk. If you are a 65-year-old retiree, a smart-sounding HPH might say that you should be 65% in bonds, with others arguing importantly that the right number is 70% or 60%. The right number is 0%. Alternatively, come up with an explanation of how the credit market is currently undervalued. I could, of course, be completely wrong, but the current credit market looks like an epic bubble. It is conventional to own a lot of bonds, but when the bubble bursts, you will conventionally lose a lot of money.” – Where Can I Find Safe Income For Retirement? Shiller P/E When to short? At the level of individual securities, the fundamental analysis and event analysis takes more time than most investors have to short stocks. In terms of shorting country markets, sectors, or parts of the capital structure, there are some readily-available resources that might be helpful in knowing when to short. For a quick heuristic on the market’s price, you might consider the Shiller P/E. This ratio is more indicative of value across business cycles because it is less impacted by fluctuating profit margins. The U.S. equity market’s Shiller P/E is currently over 43% above its historical mean of about 17. Market prices have rarely maintained such high multiples for long. For further reading on topics, including the Shiller P/E, you might like Rock Breaks Scissors: A Practical Guide to Outguessing and Outwitting Almost Everybody . U.S. equities are the fourth most expensive in the world according to this metric, behind only Japan, Ireland, and Denmark. Market Cap/GDP Market capitalization / GDP in the U.S. is another key metric. When it is high, it is a particularly important time to focus on short opportunities. Today, the U.S. market cap is about 112% of the U.S. GDP. Historically, from such lofty levels, subsequent total returns are typically less than 2% per year. The U.S. equity market is pricey on both metrics. Real returns are probably negative or too low to justify the risk. Incidentally, on both metrics, Russia is a bargain. Its Shiller P/E is about 5 and its market cap/GDP is about 18%, close to its historical minimum of 17% over the past 15 years. The inverse, leveraged Russian ETF (NYSEARCA: RUSS ) is down over 25% since our previous article on that opportunity. However, despite the move in price, it remains an attractive short. 7-Year Real Return Forecast GMO publishes a monthly chart comparing the estimated prospective annual real return over the subsequent seven years of various asset classes from current market prices. The comparison between the 6.5% long-term historical U.S. equity return and the returns from today’s levels is not favorable for today’s equity investors. Average returns will probably be around zero, with somewhat negative returns overall and only marginally positive returns for equities that GMO considers to be high quality. At least we have plenty of timber in Maine, so we have that one covered. Conclusion Part I covered the virtues of maintaining both sizing discipline and a cash balance. “Ordinary opportunity sets should lead to only ordinary position sizing, leaving extraordinarily large positions for only the rarest of opportunities. At a one percent position, one could conceivably find subsequent risk:reward opportunities to double down three times and still have a statistically diversified portfolio. Hyper-diversification accomplishes very little, but having a dozen truly uncorrelated positions accomplishes much of what correlation can offer. However, if one starts with a 5% position and doubles it three times on apparently better subsequent entry points, one is left with an over-concentrated or overleveraged portfolio.” “When everything is going horribly wrong, the comparative advantage of being more liquid than your marginal counterparty becomes extreme. So, while I do not know what the right amount of cash is, I am certain that it is better to have more. You should have more than whomever you are trading against when nothing is working in the markets. How much is that? I currently have 25% of my assets in easily accessible cash and am glad that I do. My percentage might be too low but I am virtually certain that it is not too high. Whatever opportunity cost that I pay in terms of diminished return can be quickly recouped during the next market collapse.” Part II covered some of my favorite company-specific short ideas. The ten disclosed short ideas declined from 2 to 35% since publication; none have yet to fully converge upon their intrinsic values. The average decline of 16% is over three times the S&P 500 ( SPY ) decline over the same period. The larger point is that a flexible mandate that allows one to go long or short creates an optimal environment for analytical rigor. “When someone is able to buy or short investment opportunities, he can first be analytical – gathering relevant facts, measuring value, and examining events that are likely to unlock or reveal that value. One need not be a fan, only an analyst. Regardless of whether or not you like what you are looking at, there is something to do either way. One can buy, one can short, one can ignore. One does not need to prejudge before reaching a conclusion informed by the relevant premises.” You can protect your capital by shorting expensive (and therefore risky) securities with exposures to China, biotech, and high yield credit as described above in Part III. Additionally, you can monitor the Shiller P/E ratio, the market cap/GDP, and the 7-year return forecast for a quick look at the market’s price. These tools are valuable additions to the toolkit of the prepared investor. Regardless of the specifics on how you choose to prepare for the possibility of a market crash, it is unlikely that the next half-century will look anything like the past. It is (barely) conceivable that it continues at the current pace and the S&P 500 races through 48,000. But even if it is possible, it is not a safe bet. When it comes to investing, I do not hope for or expect any single outcome. I do not hope or expect that my home will burn down either, but I still have fire extinguishers and plenty of insurance. None of this is a call to panic; it is a modest call to prepare. I would be perfectly happy to be wrong in my view that such preparation is both wise and timely. Editor’s Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

Ivy Portfolio October Update

The Ivy Portfolio spreadsheet track the 10-month moving average signals for two portfolios listed in Mebane Faber’s book The Ivy Portfolio: How to Invest Like the Top Endowments and Avoid Bear Markets . Faber discusses 5, 10, and 20 security portfolios that have trading signals based on long-term moving averages. The Ivy Portfolio spreadsheet tracks both the 5 and 10 ETF Portfolios listed in Faber’s book. When a security is trading below its 10-month simple moving average, the position is listed as “Cash.” When the security is trading above its 10-month simple moving average the positions is listed as “Invested”. The spreadsheet’s signals update once daily (typically in the late evening) using dividend/split adjusted closing price from Yahoo Finance. The 10-month simple moving average is based on the most recent 10 months including the current month’s most recent daily closing price. Even though the signals update daily, it is not an endorsement to check signals daily or trade based on daily updates. It simply gives the spreadsheet more versatility for users to check at his or her leisure. The page also displays the percentage each ETF within the Ivy 10 and Ivy 5 Portfolio is above or below the current 10-month simple moving average, using both adjusted and unadjusted data. If an ETF has paid a dividend or split within the past 10 months, then when comparing the adjusted/unadjusted data you will see differences in the percent an ETF is above/below the 10-month SMA. This could also potentially impact whether an ETF is above or below its 10-month SMA. Regardless of whether you prefer the adjusted or unadjusted data, it is important to remain consistent in your approach. My preference is to use adjusted data when evaluating signals. The current signals based on September 30th’s adjusted closing prices are below. This month Vanguard Total Bond Market ETF (NYSEARCA: BND ) is above its moving average and the balance of the ETFs, Vanguard FTSE All-World ex-US ETF (NYSEARCA: VEU ), Vanguard Small Cap ETF (NYSEARCA: VB ), Vanguard Total Stock Market ETF (NYSEARCA: VTI ), SPDR DJ International Real Estate ETF (NYSEARCA: RWX ), Vanguard Emerging Markets Stock ETF (NYSEARCA: VWO ), PowerShares DB Commodity Index Tracking (NYSEARCA: DBC ), S&P GSCI Commodity-Indexed Trust (NYSEARCA: GSG ) Vanguard REIT Index ETF (NYSEARCA: VNQ ) and iShares Barclays TIPS Bond (NYSEARCA: TIP ), are below their 10-month moving average. The spreadsheet also provides quarterly, half year, and yearly return data courtesy of Finviz. The return data is useful for those interested in overlaying a momentum strategy with the 10-month SMA strategy: (click to enlarge) I also provide a “Commission-Free” Ivy Portfolio spreadsheet as an added bonus. This document tracks the 10-month moving averages for four different portfolios designed for TD Ameritrade, Fidelity, Charles Schwab, and Vanguard commission-free ETF offers. Not all ETFs in each portfolio are commission free, as each broker limits the selection of commission-free ETFs and viable ETFs may not exist in each asset class. Other restrictions and limitations may apply depending on each broker. Below are the 10-month moving average signals (using adjusted price data) for the commission-free portfolios: (click to enlarge) (click to enlarge) Disclosures: None.

Top ETF Stories Of September

The third quarter of 2015 was utterly downbeat for the broader U.S. market as well as the global indices with the China-led rout surfacing in August and spilling over into September. Not only global growth worries but also high speculation of a Fed lift-off has made the month of September the most-watched one so far this year. In any case, according to the Stock Trader’s Almanac , September ended in red 55% of the times while S&P Dow Jones Indices indicated an average fall of 1.03% return over the last 87 years in September. As a result, after a worldwide investing massacre in August, the investing cohort must be keen to know the top financial stories of September and check their impact on the ETF world. Still a Dovish Fed Turning loads of hearsays off, the Fed remained supportive in its most talked-about September meeting. A dreaded uproar in the global investing backdrop in August led by the Chinese market crash, swooning commodities and their shockwaves on other emerging economies held the Fed back from switching on the lift-off button this September. Muted inflation and a still-strong greenback were also other forces to inhibit the Fed from policy tightening. As the Fed stayed put, some big moves in various markets and asset classes were prompted. Though the Fed has kept the option for a 2015 hike still alive, a small section of policymakers and traders have started to bet that the rates may not be hiked before 2016. Whatever the case, financial ETFs like SPDR S&P Regional Banking ETF (NYSEARCA: KRE ) and iShares Broker Dealer ETF (NYSEARCA: IAI ) and U.S. dollar ETF PowerShares DB US Dollar Bullish Fund (NYSEARCA: UUP ) were the foremost losers post Fed meeting. UUP shed 0.04%, KRE lost 1.1% and IAI was off 6.4% in the month. However, there were plenty of gainers too. Long-term Treasury bond ETFs like Vanguard Extended Duration Treasury ETF (NYSEARCA: EDV ), high-yield m-REIT ETFs like iShares FTSE NAREIT Mortgage Plus Capped Index Fund (NYSEARCA: REM ) and gold-related ETFs like SPDR Gold Shares (NYSEARCA: GLD ) and Market Vectors Gold Miners ETF (NYSEARCA: GDX ) added gains post meeting. Overall, EDV was up over 1.5% in the month but other products could not hold on to gains. REM was off 4.2% while GLD and GDX shed 0.45% and 5.6% in the month (as of September 28, 2015). Biotech Meltdown If China made August infamous, biotech did the same for September. Pricing issues in the biotech space has long been a concern but came into the limelight in September following a tweet by the Democratic presidential candidate Hillary Clinton. Her tweet raised concerns on over pricing on life-saving drugs at the end of the month. Questions over biotech pricing came on the heels of a 5,455% price hike (in about two months) of a drug called Daraprim, used to treat malaria and toxoplasmosis. This gigantic leap in pricing action was taken by a privately held biotech company Turing Pharmaceuticals. Not only Turing Pharmaceuticals, Valeant Pharmaceuticals International Inc. (NYSE: VRX ) is also likely to be summoned by Democrats on the House oversight committee for hiking 525% and 212% prices for two heart drugs. The talks pulled VRX shares down by 16.5% on September 28 and hit all biotech ETFs. In fact, growing pains for biotech investing led the biggest related ETF iShares Nasdaq Biotechnology (NASDAQ: IBB ) to incur the largest weekly loss in seven years. IBB was down over 15% in the last one month while ETFs like SPDR S&P Biotech ETF (NYSEARCA: XBI ), Medical Breakthroughs ETF (NYSEARCA: SBIO ) and BioShares Biotechnology Clinical Trials Fund (NASDAQ: BBC ) were off 15.4%, 16.5% and 15%, respectively. Volkswagen Scandal This dealt quite a blow to the entire auto industry. The iconic German carmaker Volkswagen AG ( OTCQX:VLKAY ) has been accused of tricking on the Environmental Protection Agency (EPA) test. Per EPA, Volkswagen had set up a software algorithm which allowed it to mislead U.S. emissions tests and the carmaker has admitted the charge. This immediately weighed on the key auto industry of Germany as other automakers have also been hit. Germany ETFs like iShares MSCI Germany ETF (NYSEARCA: EWG ), Recon Capital DAX Germany ETF (NASDAQ: DAX ), Germany AlphaDEX Fund (NASDAQ: FGM ) and db X-trackers MSCI Germany Hedged Equity Fund (NYSEARCA: DBGR ) were hit hard on this car scandal and registered a steep retreat in the month. The funds were off over 6.6%, 6.5%, 6.4% and 5.15 respectively in September. Original Post Editor’s Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.